The Cancer Biology and Biotechnology Research Program at the University of New Mexico Cancer Center is a highly interactive transdisciplinary program with 24 Program Members from 6 Departments in the UNM School of Medicine (Biochemistry and Molecular Biology, Cell Biology and Physiology, Medicine, Molecular Genefics and Microbiology, Neurology, and Pathology), the UNM College of Pharmacy, 3 Departments on the UNM Main Campus (Biology, Chemical and Nuclear Engineering, and Physics and Astronomy), New Mexico State University (Chemistry), and Sandia and Los Alamos Nafional Laboratories. The Program has two scientific themes; the first: Chromosome Dynamics and Macromolecular Interactions has the goals of (1) discovering the fundamental mechanisms of tumorigenesis through studies of epigenefic, transcripfional, cell growth control, and DNA damage repair pathways in cancer cells and model organisms; and (2) exploiting studies of viral protein-nucleic acid interacfions for translafion into new dlagnosfic or therapeufic platforms. The second program theme: Biotechnology and Target Screening has the overall goal of discovering and validating novel targets and small molecules from these fundamental regulatory pathways for cancer diagnosis, screening, prevention, and therapy. To achieve the goals of this second theme, program members develop and utilize (1) high-throughput small molecule screening, high performance compufing, cheminformafics, and animal modeling; (2) novel isotopes and imaging; and (3) micro- and nanotechnology to discover, screen, and model new cancer targets. Since the prior NCI CCSG review in 2005, the Program's funding, intraprogrammafic, and inter-programmafic interacfions have all increased dramafically. Program members direct one of only 9 nafional, mulfi-invesfigator NIH Roadmap-funded Center Grants for target screening and chemical biology: The UNM Center for Molecular Discovery (U54MH084690) which is collaborating with each UNM Cancer Center Research Program and several other NCI Cancer Centers to screen and characterize over 30 novel cancer targets. Program members also recenfiy received nofice of the funding of two highly compefifive NCI ARRA Challenge Grants {RC2CA148982; RC1EB/CA010617). As of September 2009, Program Members at the UNM Cancer Center and its consortium institufions held $9,538,635 in total annual direct funding (represenfing an 80% increase in funding since 2005) of which $8,365,143 was peer-reviewed ($1,537,027 from NCI and $6,828,116 from NIH, NSF, DOD, and DOE). Program members at New Mexico State University held an additional $2,965,296 in annual peer-reviewed funding. In 2008, program members published a total of 53 cancer-relevant publicafions, of which 27% were intra-programmafic and 48% were inter-programmatic.

Public Health Relevance

Cancer is a multifactorial disease that requires transdisciplinary approaches to understand its etiology and translate these discoveries to more effective diagnostics and therapeutics. The goals of The Cancer Biology and Biotechnology Program are to study the most fundamental cellular pathways that are perturbed in human cancers and that promote cancer efiology and progression and to develop and use the most innovative science and technology to discover and characterize new cellular targets that can be used to diagnosis, screen, prevent, and treat human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA118100-08S2
Application #
8545062
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
8
Fiscal Year
2012
Total Cost
$4,167
Indirect Cost
$1,407
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Guo, Yan; Yu, Hui; Wang, Jing et al. (2018) The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel) 9:
Hatch, Ellen W; Geeze, Mary Beth; Martin, Cheyenne et al. (2018) Variability of PD-L1 expression in mastocytosis. Blood Adv 2:189-199
Frerich, Candace A; Brayer, Kathryn J; Painter, Brandon M et al. (2018) Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget 9:7341-7358
Kinney, Anita Y; Howell, Rachel; Ruckman, Rachel et al. (2018) Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. Contemp Clin Trials 73:123-135
Tasnim, Humayra; Fricke, G Matthew; Byrum, Janie R et al. (2018) Quantitative Measurement of Naïve T Cell Association With Dendritic Cells, FRCs, and Blood Vessels in Lymph Nodes. Front Immunol 9:1571
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Castleman, Moriah J; Pokhrel, Srijana; Triplett, Kathleen D et al. (2018) Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by ?-Hemolysin. J Immunol 200:657-668
Barton, Matthias; Filardo, Edward J; Lolait, Stephen J et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol 176:4-15
Prossnitz, Eric R (2018) GPER modulators: Opportunity Nox on the heels of a class Akt. J Steroid Biochem Mol Biol 176:73-81
Perez, Dominique R; Nickl, Christian K; Waller, Anna et al. (2018) High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discov 23:732-741

Showing the most recent 10 out of 344 publications